Aurisco Pharmaceutical Hits Day High with Strong 6.63% Intraday Surge

Aurisco Pharmaceutical Co., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has shown significant activity today, with its stock rising by 6.63% on March 27, 2026. The stock reached an intraday high of CNY 26.98, reflecting a strong performance compared to the broader market, as the China Shanghai Composite index only increased by 0.63% on the same day. Over the past week, Aurisco has outperformed the Shanghai Composite, gaining 2.85% while the index declined by 1.09%. Year-to-date, the company has achieved a 6.51% increase, contrasting with the index's negative performance of -1.39%. Notably, Aurisco's one-year performance stands at 22.22%, surpassing the Shanghai Composite's 16.01% gain. Financially, Aurisco maintains a return on equity (ROE) of 16.35% and a price-to-book ratio of 3.73, indicating a fair valuation. The company also boasts a high dividend yield of 1.3%. Despite some challenges reflected in its inventory and debtors turnover ratios, Aurisco's overall performance metrics suggest a resilient position in the market.